<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004486</url>
  </required_header>
  <id_info>
    <org_study_id>199/14266</org_study_id>
    <secondary_id>MTS-FDR001520</secondary_id>
    <secondary_id>MTS-GCO-96-713</secondary_id>
    <nct_id>NCT00004486</nct_id>
  </id_info>
  <brief_title>Randomized Study of Fluoxetine in Children and Adolescents With Autism</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Evaluate the efficacy of fluoxetine on social and language deficits, global&#xD;
      severity and compulsive dimensions of children and adolescents with autism.&#xD;
&#xD;
      II. Assess the effectiveness of this treatment regimen on neurocognitive deficits in this&#xD;
      patient population.&#xD;
&#xD;
      III. Compare the baseline compulsive severity and treatment outcome in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, crossover study.&#xD;
      All patients receive oral placebo daily during week 0.&#xD;
&#xD;
      Patients are randomized to receive either oral fluoxetine or oral placebo daily on weeks 1-8.&#xD;
      Patients then crossover to receive treatment on the other arm during weeks 12-20.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <completion_date>December 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Autism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluoxetine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Meets diagnostic criteria for autism&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 months since prior electroconvulsive therapy&#xD;
&#xD;
          -  At least 1 month since prior investigational drugs or treatment with any drug known to&#xD;
             cause major organ toxicity&#xD;
&#xD;
          -  At least 2 weeks since prior monoamine oxidase inhibitors&#xD;
&#xD;
          -  At least 6 weeks since prior long acting phenothiazines&#xD;
&#xD;
          -  At least 1 week since prior other psychotropic drugs&#xD;
&#xD;
          -  No prior fluoxetine of 20 mg/day for 6 weeks&#xD;
&#xD;
          -  At least 6 weeks since prior fluoxetine&#xD;
&#xD;
          -  No concurrent use of terfenadine (Seldane) or astemizole (Hismanal)&#xD;
&#xD;
          -  No concurrent electroconvulsive therapy or other psychotropic drugs (unless otherwise&#xD;
             permitted)&#xD;
&#xD;
          -  Prior participation in another serotonin reuptake inhibitor trial allowed&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hematopoietic: No significant hematopoietic disease&#xD;
&#xD;
        Hepatic: No prior or concurrent liver disease&#xD;
&#xD;
        Renal: No prior or concurrent kidney disease&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No significant cardiovascular disease&#xD;
&#xD;
          -  No abnormal EKG&#xD;
&#xD;
        Neurological:&#xD;
&#xD;
          -  No prior seizure disorder or high risk development of seizures&#xD;
&#xD;
          -  No prior cerebrovascular disease&#xD;
&#xD;
          -  No prior brain trauma&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No unstable major medical illness or systemic disease&#xD;
&#xD;
          -  No moderate or severe mental retardation and motor deficits (IQ less than 50)&#xD;
&#xD;
          -  No family history of bipolar disorder&#xD;
&#xD;
          -  No prior or concurrent other mental disorders (e.g., schizophrenia, schizoaffective,&#xD;
             organic, or bipolar disorders)&#xD;
&#xD;
          -  No significant autoaggressive behavior or serious suicidal risk&#xD;
&#xD;
          -  No prior or concurrent gastrointestinal conditions&#xD;
&#xD;
          -  No unstable endocrine disease (e.g., hypo or hyperthyroidism)&#xD;
&#xD;
          -  No prior or concurrent malignancy&#xD;
&#xD;
          -  Must be able to tolerate tapering of psychoactive medication&#xD;
&#xD;
          -  No history of hypersensitivity or severe side effects to fluoxetine or other serotonin&#xD;
             reuptake inhibitors&#xD;
&#xD;
          -  No history of severe personality disorder or noncompliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Hollander</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005 Mar;30(3):582-9. doi: 10.1038/sj.npp.1300627.</citation>
    <PMID>15602505</PMID>
  </results_reference>
  <verification_date>December 2000</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>autism</keyword>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

